Chuck Williams leaves after serving for six years as Pfizer’s first CTO/CIO. He’s replaced by Walt Hauck, who had been at Pfizer since 1995.
Pfizer creates emerging markets business unit
Pilots the eCard patient loyalty card in the Philippines
CIO Hauck leaves, replaced by interim CIO Rich Nossek.
Pfizer starts development of CUE, a cloud-based CRM application for sales agents marketing pharmaceuticals to physicians
(October) Pfizer acquires Wyeth for $68 billion, spending another $569 million on integration. Jeff Keisling, former Wyeth CIO, is appointed Pfizer CIO, replacing Nossek.
Pfizer spends another $1 billion on Wyeth integration, completing 500 projects. Achieves $2 billion in cost reductions.
R&D spending is $9.4 billion
(December) CEO Jeff Kindler resigns under pressure from the board as other senior executives reportedly agitate for change at the top
Ian Read, former head of Pfizer’s worldwide biopharmaceutical business, takes over and continues cost-cutting plans already in progress
Workforce totals 110,600, down 10,100 from the October 2009 completion of the Wyeth acquisition
Pfizer plans to reduce R&D spending by between $1.1 billion and $1.4 billion, to between $8 billion and $8.5 billion
(November) Lipitor patent expires
Pfizer plans to cut $4 billion to $5 billion in costs by the end of the year. This includes another $1.5 billion to $2 billion from R&D, cutting that budget to $6.5 billion to $7 billion.
Viagra patent expires
Follow Senior Editor Kim S. Nash on Twitter: @knash99.